e8vk
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
April 23, 2008
Date of report (Date of earliest event reported)
SurModics,
Inc.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Minnesota
|
|
0-23837
|
|
41-1356149 |
|
|
|
|
|
(State of Incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer |
|
|
|
|
Identification No.) |
|
|
|
9924 West
74th Street |
|
|
Eden Prairie, Minnesota
|
|
55344 |
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
(952) 829-2700
(Registrants Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02. Results of Operations And Financial Condition.
On April 23, 2008, SurModics, Inc. issued a press release announcing the results for the
quarter ended March 31, 2008. A copy of the full text of the press release is furnished as Exhibit
99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
|
(a) |
|
Financial Statements: None. |
|
|
(b) |
|
Pro forma financial information: None. |
|
|
(c) |
|
Shell company transactions: None. |
|
|
(d) |
|
Exhibits: 99.1 Press Release dated April 23, 2008. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
SURMODICS, INC.
|
|
Date: April 23, 2008 |
/s/ Philip D. Ankeny
|
|
|
Philip D. Ankeny |
|
|
Chief Financial Officer |
|
|
EXHIBIT INDEX
|
|
|
Exhibit |
|
|
Number |
|
Description |
|
|
|
99.1
|
|
Press Release dated April 23, 2008. |
exv99w1
Exhibit 99.1
NEWS RELEASE
SurModics Reports Record Total and Legacy Business
Revenue in Second Quarter 2008
EDEN PRAIRIE, Minnesota April 23, 2008 SurModics, Inc. (Nasdaq: SRDX), a leading provider
of surface modification and drug delivery technologies to the healthcare industry, today
reported financial results for the second fiscal quarter ended March 31, 2008.
Second Quarter Highlights:
|
|
Record total revenue of $25.7 million, up 48% year-over-year |
|
o |
|
Record legacy business revenue (excluding Brookwood Pharmaceuticals and BioFX
Laboratories acquisitions), up 12% year-over-year |
|
|
o |
|
Record Brookwood Pharmaceuticals revenue of $5.2 million |
|
|
o |
|
Record non-CYPHER-related revenue, up 90% year-over-year; up 34% excluding
acquisitions |
|
|
o |
|
Double-digit year-over-year revenue growth in all three operating segments: |
|
§ |
|
Drug Delivery up 93% |
|
|
§ |
|
Hydrophilic and Other up 26% |
|
|
§ |
|
In Vitro up 19% |
|
o |
|
Operating income of $7.2 million |
|
|
o |
|
Net income of $5.1 million |
|
|
o |
|
Diluted EPS of $0.28 |
|
|
Non-GAAP results (adjusting for accounting treatment of Merck agreement): |
|
o |
|
Adjusted total revenue of $28.5 million |
|
|
o |
|
Adjusted operating income of $9.9 million |
|
|
o |
|
Adjusted net income of $6.8 million |
|
|
o |
|
Adjusted diluted EPS of $0.37 |
|
|
Operating cash flow of $4.5 million |
|
|
|
Four new licenses signed with SurModics customers |
|
|
|
Four new customer products introduced |
|
|
|
Repurchased $2.6 million of SurModics stock |
- more -
SurModics Reports Record Total and Legacy Business Revenue in Second Quarter 2008
Page 2
SurModics generated record total revenue and double-digit revenue growth in all three of
our operating segments for the second consecutive quarter, said Bruce Barclay, president and CEO. We
are particularly gratified to achieve record revenue for the second
consecutive quarter in our
legacy business despite a 28% year-over-year
decrease in Cypher stent-related revenue. Further Brookwood Pharmaceuticals generated record
revenue, and both Brookwood and BioFX again contributed to overall earnings this quarter. These results
demonstrate the significant benefits of our broad and diverse
technology portfolio.
Our collaboration with Merck in ophthalmology
continues to progress extremely well. In January we
announced an extension of our license agreement with Merck, and we generated a record number of
billable hours with Merck in the quarter. As of the end of the quarter, our total Merck
deferred revenue balance had grown to $24.9 million, continued Barclay. The achievement of
three of our fiscal 2008 goals added to the highlights of our second
quarter performance. First, we announced the first in-human use of the SynBiosys biodegradable polymer on
our customer CardioMinds drug-eluting stent. Second, in
February, Medtronic announced their
U.S. launch of the Endeavor® Coronary Stent
System which uses SurModics hydrophilic
technology. Third, we generated $15.6 million in cash from our paid development activities
so far this fiscal year, already surpassing our goal of $10 million. We are making excellent progress on
our strategic plan for sustainable growth, and continue to believe in our ability to achieve
our fiscal 2008 company goals as well as our long-term objectives.
For the
second quarter of fiscal 2008, revenue was $25.7 million, an increase of 48% from $17.4
million in the year earlier period. Total operating expenses, including product costs, were
$18.5 million, which roughly doubled from $9.3 million last year. Operating income was $7.2 million,
a decrease of 11% compared with $8.1 million in the prior-year period. Net income was $5.1
million, a decrease of 10% from $5.7 million in the same period
last year. Diluted net income per
share was $0.28, a 10% decrease from $0.31 in the second quarter of fiscal 2007. Earnings
growth did not keep pace with revenue growth primarily as a result of
the accounting treatment relating to our Merck agreement, higher stock-based compensation costs associated with recent board
transitions, and a changing mix of revenue sources.
SurModics Reports Record Total and Legacy Business Revenue in Second Quarter 2008
Page 3
For the first six months of fiscal 2008, revenue was $49.5 million, compared with $34.1 million
in the year earlier period. Operating income was $14.8 million, compared with $16.2 million in
the prior year period; net income was $10.8 million, compared with $11.7 million in the year
earlier period; and diluted net income per share was $0.58, compared with $0.64 in the first six
months of fiscal 2007.
This quarter we are providing shareholders with a more transparent picture of ongoing
operations at SurModics by presenting supplemental non-GAAP disclosure related to the Merck
agreement accounting treatment, said Phil Ankeny, senior vice president and chief financial
officer. We believe that this supplemental non-GAAP disclosure complements our GAAP
reporting, and allows the investment community to better understand current performance by
showing what our results would have looked like had we fully recognized as revenue all of the
items related to our significant collaboration with Merck, compared to amortizing the amounts,
as we do under the applicable accounting treatment. Because the Merck agreement is so
significant to our business, and given the effect the associated
accounting has on our
reported results, we are presenting this new non-GAAP disclosure to help investors understand
the impact of that single agreement.
On a
non-GAAP basis (adjusting for the accounting treatment of the Merck
agreement), for the three-month period ended March 31, 2008, total revenue was $28.5
million, operating income was $9.9 million, net income was $6.8 million, and diluted net income
per share was $0.37. On a non-GAAP basis, for the six-month period ending March 31, 2008, total
revenue was $53.8 million, operating income was $19.0 million, net income was $13.3 million,
and diluted net income per share was $0.72. As of March 31, 2008, the deferred revenue balance
associated with the Merck agreement was $24.9 million.
SurModics cash and investment balances totaled $80.9 million as of March 31, 2008, up from
$72.5 million as of December 31, 2007. Operating cash flow for the quarter was $4.5 million,
compared with $4.7 million in the prior year period. SurModics
also initiated its second share
repurchase program in the quarter with repurchases totaling $2.6 million.
SurModics Reports Record Total and Legacy Business Revenue in Second Quarter 2008
Page 4
SurModics pipeline continues to grow. The company signed four new licenses in the second quarter, bringing the
fiscal year-to-date total to 13, and has a goal of signing 18 new licenses in fiscal 2008.
SurModics customers launched four new product classes in the marketplace during the quarter,
bringing the fiscal year-to-date total to six, as the company works toward its goal of 10
launches in fiscal 2008. As of March 31, 2008, SurModics customers had 100 licensed product
classes generating royalty revenue, up from 95 in the prior-year period; the total number of
licensed product classes not yet launched was 103, compared with 91 in the prior-year period;
and major non-licensed opportunities totaled 90, compared with 77 a year ago. In total,
SurModics now has 193 potential commercial products in development.
Live Webcast
SurModics will host a webcast at 5:00 p.m. ET (4:00 p.m. CT) today to discuss the quarterly
results. To access the webcast, go to the investor relations portion of the companys website at
www.surmodics.com, and click on the second quarter webcast icon. If you do not have access to the
Internet and want to listen to the audio by phone, dial 800-867-1054. A replay of the second
quarter conference call will be available by dialing 800-405-2236 and entering conference call ID
11112931. The audio replay will be available beginning at 7:00 p.m. CT on Wednesday, April 23,
until 7:00 p.m. CT on Wednesday, April 30.
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification and drug delivery technologies to the
healthcare industry. SurModics partners with the worlds foremost medical device, pharmaceutical
and life science companies to develop and commercialize innovative products that result in improved
patient outcomes. Core offerings include: drug delivery technologies (coatings, microparticles, and
implants); surface modification coating technologies that impart lubricity, prohealing, and
biocompatibility capabilities; and components for in vitro diagnostic test kits and
specialized surfaces for cell culture and microarrays. Collaborative efforts include a sustained
drug-delivery system in human trials for treatment of retinal disease and the drug-delivery polymer
matrix on the first-to-market drug-eluting coronary stent. SurModics is headquartered in Eden
Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. For more information about the
company, visit www.surmodics.com. The content of SurModics website is not part of this release or
part of any filings the company makes with the SEC.
SurModics Reports Record Total and Legacy Business Revenue in Second Quarter 2008
Page 5
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements. Statements that are not historical or
current facts, including statements about beliefs and expectations, such as, statements about our
ability to achieve our fiscal 2008 corporate goals and long-term objectives and statements
regarding our pipeline, are forward-looking statements. Forward-looking statements involve inherent
risks and uncertainties, and important factors could cause actual results to differ materially from
those anticipated, including the following: (1) realizing the full potential benefits of the
companys agreement with Merck requires the development of new products and applications of
technology; (2) costs or difficulties relating to the integration of the businesses of Brookwood
Pharmaceuticals and BioFX Laboratories with SurModics business may be greater than expected and
may adversely affect the companys results of operations and financial condition; (3) our reliance
on third parties, developments in the regulatory environment, as well as market and general
economic conditions, may adversely affect our business operations and profitability and our ability
to achieve our fiscal 2008 corporate goals and to realize the potential of our pipeline; (4)
failure to obtain intellectual property rights protecting our proprietary technologies, or the
expiration or loss of such rights, could have a material adverse effect on our business, financial
condition and results of operations; and (5) other factors identified under Risk Factors in Part
I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007, and
updated in our subsequent reports filed with the SEC. These reports are available in the Investors
section of our website at www.surmodics.com and at the SEC website at
www.sec.gov. Forward-looking
statements speak only as of the date they are made, and we undertake no obligation to update them
in light of new information or future events.
Use of Non-GAAP Financial Information
In addition to reporting financial results in accordance with generally accepted accounting
principles, or GAAP, SurModics is reporting non-GAAP financial results including non-GAAP revenue,
non-GAAP net income and non-GAAP diluted net income per share. We believe that these non-GAAP measures
provide meaningful insight into our operating performance as it relates to our Merck agreement
accounting treatment and
provide an alternative perspective of our results of operations. We use these non-GAAP measures to
assess our operating performance and
SurModics Reports Record Total and Legacy Business Revenue in Second Quarter 2008
Page 6
presentation
of these non-GAAP measures allows investors to review our results of operations from the same perspective as
management and our board of directors. We believe these non-GAAP measures facilitate investors
analysis and comparisons of our current results of operations and provide insight into the
prospects of our future performance. We also believe that the non-GAAP measures are useful to
investors because they provide supplemental information that research analysts frequently use. The
method we use to produce non-GAAP results is not in accordance with GAAP and may differ from the
methods used by other companies. These non-GAAP results should not be regarded as a substitute for
corresponding GAAP measures but instead should be utilized as a supplemental measure of operating
performance in evaluating our business. Non-GAAP measures do have limitations in that they do not
reflect certain items that may have a material impact upon our reported financial results. As such,
these non-GAAP measures should be viewed in conjunction with both our financial statements prepared
in accordance with GAAP and the reconciliation of the supplemental non-GAAP financial measures to
the comparable GAAP results provided for each period presented, which are attached to this release.
Contacts
Maggie Knack, Director, Investor Relations, or
Phil Ankeny, Senior Vice President and Chief Financial Officer
(952) 829-2700
- more -
SurModics Reports Record Total and Legacy Business Revenue in Second Quarter 2008
Page 7
SurModics, Inc. and Subsidiaries
Condensed Consolidated Statements of Income
(In thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
|
|
March 31, |
|
March 31, |
|
|
|
2008 |
|
|
2007 |
|
|
2008 |
|
|
2007 |
|
|
|
(Unaudited) |
|
|
(Unaudited) |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalties and license fees |
|
$ |
13,809 |
|
|
$ |
13,028 |
|
|
$ |
26,987 |
|
|
$ |
26,247 |
|
Product sales |
|
|
4,700 |
|
|
|
3,381 |
|
|
|
9,907 |
|
|
|
6,107 |
|
Research & development |
|
|
7,198 |
|
|
|
953 |
|
|
|
12,642 |
|
|
|
1,748 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
25,707 |
|
|
|
17,362 |
|
|
|
49,536 |
|
|
|
34,102 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product costs |
|
|
2,154 |
|
|
|
1,092 |
|
|
|
4,129 |
|
|
|
2,179 |
|
Research & development |
|
|
10,370 |
|
|
|
5,717 |
|
|
|
19,903 |
|
|
|
10,924 |
|
Selling, general & administrative |
|
|
6,002 |
|
|
|
2,468 |
|
|
|
10,751 |
|
|
|
4,805 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
18,526 |
|
|
|
9,277 |
|
|
|
34,783 |
|
|
|
17,908 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations |
|
|
7,181 |
|
|
|
8,085 |
|
|
|
14,753 |
|
|
|
16,194 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment income |
|
|
1,184 |
|
|
|
1,172 |
|
|
|
2,904 |
|
|
|
2,501 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
|
8,365 |
|
|
|
9,257 |
|
|
|
17,657 |
|
|
|
18,695 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax provision |
|
|
(3,258 |
) |
|
|
(3,582 |
) |
|
|
(6,903 |
) |
|
|
(7,029 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
5,107 |
|
|
$ |
5,675 |
|
|
$ |
10,754 |
|
|
$ |
11,666 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic net income per share |
|
$ |
0.28 |
|
|
$ |
0.31 |
|
|
$ |
0.60 |
|
|
$ |
0.64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income per share |
|
$ |
0.28 |
|
|
$ |
0.31 |
|
|
$ |
0.58 |
|
|
$ |
0.64 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
18,102 |
|
|
|
18,017 |
|
|
|
18,055 |
|
|
|
18,232 |
|
Diluted |
|
|
18,428 |
|
|
|
18,133 |
|
|
|
18,421 |
|
|
|
18,342 |
|
SurModics Reports Record Total and Legacy Business Revenue in Second Quarter 2008
Page 8
SurModics, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
September 30, |
|
|
|
2008 |
|
|
2007 |
|
|
|
(Unaudited) |
|
Assets |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash & investments |
|
$ |
37,829 |
|
|
$ |
26,308 |
|
Accounts receivable |
|
|
17,821 |
|
|
|
16,138 |
|
Inventories |
|
|
2,591 |
|
|
|
2,497 |
|
Other current assets |
|
|
6,354 |
|
|
|
2,952 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
64,595 |
|
|
|
47,895 |
|
|
|
|
|
|
|
|
|
|
Property & equipment, net |
|
|
20,934 |
|
|
|
19,738 |
|
Restricted cash |
|
|
1,630 |
|
|
|
|
|
Long-term investments |
|
|
43,089 |
|
|
|
43,917 |
|
Other assets |
|
|
54,789 |
|
|
|
59,781 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
$ |
185,037 |
|
|
$ |
171,331 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities & Stockholders Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities* |
|
$ |
12,061 |
|
|
$ |
14,266 |
|
|
|
|
|
|
|
|
|
|
Deferred revenue (current
and long-term) |
|
|
28,114 |
|
|
|
25,891 |
|
|
|
|
|
|
|
|
|
|
Other liabilities |
|
|
1,597 |
|
|
|
252 |
|
|
|
|
|
|
|
|
|
|
Total stockholders equity |
|
|
143,265 |
|
|
|
130,922 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities & stockholders equity |
|
$ |
185,037 |
|
|
$ |
171,331 |
|
|
|
|
|
|
|
|
|
|
|
* |
|
Current liabilities exclude current portion of deferred revenue. |
- more -
SurModics
Reports Second Quarter 2008 Results
Page 9
SurModics, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended |
|
|
|
March 31, |
|
|
|
2008 |
|
|
2007 |
|
|
|
(Unaudited) |
|
Operating Activities |
|
|
|
|
|
|
|
|
Net income |
|
$ |
10,754 |
|
|
$ |
11,666 |
|
Depreciation and amortization |
|
|
2,993 |
|
|
|
1,960 |
|
Stock-based compensation |
|
|
5,351 |
|
|
|
2,870 |
|
Net other operating activities |
|
|
(2,727 |
) |
|
|
(1,069 |
) |
Change in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(1,683 |
) |
|
|
4,613 |
|
Accounts payable and accrued liabilities |
|
|
31 |
|
|
|
(1,102 |
) |
Income taxes |
|
|
(7,603 |
) |
|
|
(2,349 |
) |
Deferred revenue |
|
|
1,988 |
|
|
|
375 |
|
Net change in other operating assets and liabilities |
|
|
(160 |
) |
|
|
(510 |
) |
|
|
|
|
|
|
|
Net cash provided by operating activities |
|
|
8,944 |
|
|
|
16,454 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investing Activities |
|
|
|
|
|
|
|
|
Net purchases of property and equipment |
|
|
(2,030 |
) |
|
|
(1,610 |
) |
Cash restricted for land purchase |
|
|
(1,630 |
) |
|
|
|
|
Collection of notes receivable |
|
|
5,870 |
|
|
|
261 |
|
Net other investing activities |
|
|
3,440 |
|
|
|
20,311 |
|
|
|
|
|
|
|
|
Net cash provided by investing activities |
|
|
5,650 |
|
|
|
18,962 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financing Activities |
|
|
|
|
|
|
|
|
Issuance of common stock |
|
|
1,848 |
|
|
|
2,063 |
|
Purchase of common stock to fund employee taxes |
|
|
(1,450 |
) |
|
|
(178 |
) |
Repurchase of common stock |
|
|
(2,601 |
) |
|
|
(35,030 |
) |
Net other financing activities |
|
|
543 |
|
|
|
|
|
|
|
|
|
|
|
|
Net cash used in financing activities |
|
|
(1,660 |
) |
|
|
(33,145 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net change in cash and cash equivalents |
|
|
12,934 |
|
|
|
2,271 |
|
|
|
|
|
|
|
|
|
|
Cash and Cash Equivalents |
|
|
|
|
|
|
|
|
Beginning of period |
|
|
13,812 |
|
|
|
3,751 |
|
|
|
|
|
|
|
|
End of period |
|
$ |
26,746 |
|
|
$ |
6,022 |
|
|
|
|
|
|
|
|
- more -
SurModics
Reports Second Quarter 2008 Results
Page 10
SurModics, Inc. and Subsidiaries
Supplemental Non-GAAP Information
For the Three Months Ended March 31, 2008
(in thousands, except per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
Merck Agreement Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted |
|
|
|
As Reported |
|
|
Revenue |
|
|
Billed |
|
|
Non- |
|
|
|
GAAP (1) |
|
|
Recognized |
|
|
Activity |
|
|
GAAP (2) |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalties and license fees |
|
$ |
13,809 |
|
|
$ |
(406) |
(3) |
|
$ |
2,000 |
(4) |
|
$ |
15,403 |
|
Product sales |
|
|
4,700 |
|
|
|
|
|
|
|
|
|
|
|
4,700 |
|
Research and development |
|
|
7,198 |
|
|
|
(667) |
(3) |
|
|
1,837 |
(4) |
|
|
8,368 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
$ |
25,707 |
|
|
$ |
(1,073 |
) |
|
$ |
3,837 |
|
|
$ |
28,471 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations |
|
$ |
7,181 |
|
|
$ |
(1,073 |
) |
|
$ |
3,837 |
|
|
$ |
9,945 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
5,107 |
|
|
$ |
(655) |
(5) |
|
$ |
2,343 |
(5) |
|
$ |
6,795 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income per share (6) |
|
$ |
0.28 |
|
|
|
|
|
|
|
|
|
|
$ |
0.37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at |
|
|
Revenue |
|
|
Billed |
|
|
Balance at |
|
|
|
December
31, 2007 |
|
|
Recognized |
|
|
Activity |
|
|
March
31, 2008 |
|
Merck deferred revenue (7) |
|
$ |
22,113 |
|
|
$ |
(1,073 |
) |
|
$ |
3,837 |
|
|
$ |
24,877 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Reflects operating results in accordance with U.S. generally accepted accounting principles
(GAAP). |
|
(2) |
|
Adjusted Non-GAAP amounts exclude the revenue recognized in the period associated with the
Merck agreement under GAAP and include amounts billed associated with
the Merck agreement. |
|
(3) |
|
Reflects recognition of revenue for the Merck agreement in accordance with GAAP for the
period presented. |
|
(4) |
|
Reflects amounts billed under the Merck agreement for the period presented. |
|
(5) |
|
Reflects the after tax impact of the adjustments utilizing the Companys effective tax rate
for the period presented. |
|
(6) |
|
Diluted net income per share is calculated using the diluted weighted average shares
outstanding for the period presented. |
|
(7) |
|
Reflects the activity for the period presented in the deferred revenue balance sheet account
associated with the Merck agreement. |
- more -
SurModics
Reports Second Quarter 2008 Results
Page 11
SurModics, Inc. and Subsidiaries
Supplemental Non-GAAP Information
For the Six Months Ended March 31, 2008
(in thousands, except per share data)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Merck Agreement Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted |
|
|
|
As Reported |
|
|
Revenue |
|
|
|
|
|
|
Non- |
|
|
|
GAAP (1) |
|
|
Recognized |
|
|
Billed Activity |
|
|
GAAP (2) |
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalties and license fees |
|
$ |
26,987 |
|
|
$ |
(719) |
(3) |
|
$ |
2,000 |
(4) |
|
$ |
28,268 |
|
Product sales |
|
|
9,907 |
|
|
|
|
|
|
|
|
|
|
|
9,907 |
|
Research and development |
|
|
12,642 |
|
|
|
(740) |
(3) |
|
|
3,712 |
(4) |
|
|
15,614 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
$ |
49,536 |
|
|
$ |
(1,459 |
) |
|
$ |
5,712 |
|
|
$ |
53,789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations |
|
$ |
14,753 |
|
|
$ |
(1,459 |
) |
|
$ |
5,712 |
|
|
$ |
19,006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
10,754 |
|
|
$ |
(889) |
(5) |
|
$ |
3,479 |
(5) |
|
$ |
13,344 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted net income per share (6) |
|
$ |
0.58 |
|
|
|
|
|
|
|
|
|
|
$ |
0.72 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at |
|
|
Revenue |
|
|
|
|
|
|
Balance at |
|
|
|
December
31, 2007 |
|
|
Recognized |
|
|
Billed Activity |
|
|
March
31, 2008 |
|
Merck deferred revenue (7) |
|
$ |
20,624 |
|
|
$ |
(1,459 |
) |
|
$ |
5,712 |
|
|
$ |
24,877 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Reflects operating results in accordance with U.S. generally accepted accounting principles
(GAAP). |
|
(2) |
|
Adjusted Non-GAAP amounts exclude the revenue recognized in the period associated with the
Merck agreement under GAAP and include amounts billed associated with
the Merck agreement. |
|
(3) |
|
Reflects recognition of revenue for the Merck agreement in accordance with GAAP for the
period presented. |
|
(4) |
|
Reflects amounts billed under the Merck agreement for the period presented. |
|
(5) |
|
Reflects the after tax impact of the adjustments utilizing the Companys effective tax rate
for the period presented. |
|
(6) |
|
Diluted net income per share is calculated using the diluted weighted average shares
outstanding for the period presented. |
|
(7) |
|
Reflects the activity for the period presented in the deferred revenue balance sheet account
associated with the Merck agreement. |
# # #